Market Overview:
Platelet-rich plasma (PRP) is having more platelets typically found in the blood. The general concentration of platelets is varied nearly 5 to 10 times than usual. PRP is injected into injured areas in the body parts and also used to improve healing after surgery from injuries. The major factors which affect the PRP treatments include the area of the body, the overall health of patients, injury is acute or chronic. Platelet-rich plasma (PRP) is a recent development within the expanding field of regenerative medicine.
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Forecast Period | 2022-2027 |
Historical Period | 2017-2021 |
Unit | Value (USD Million) |
Key Companies Profiled | AdiStem Ltd. (Australia), Arthrex, Inc. (United States), Biomet, Inc. (United States), Cesca Therapeutics, Inc. (United States), DePuy Synthes, Inc. (United States), EmCyte Corporation, Exactech, Inc. (United States), Harvest Technologies Corp., Nuo Therapeutics, Inc. and Regen Lab SA (Switzerland) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility |
AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics by major and emerging geographies across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Key Players of Platelet Rich Plasma Market Study:
AdiStem Ltd. (Australia), Arthrex, Inc. (United States), Biomet, Inc. (United States), Cesca Therapeutics, Inc. (United States), DePuy Synthes, Inc. (United States), EmCyte Corporation, Exactech, Inc. (United States), Harvest Technologies Corp., Nuo Therapeutics, Inc. and Regen Lab SA (Switzerland)
In the last few years, Global market of Platelet Rich Plasma developed rapidly, with an average growth rate of 11.1% in 2021, Global revenue of Platelet Rich Plasma is nearly USD436.1 Million. Major factors driving the market are Increase Number of Chronic Tendon Injuries Treatment.
On the basis of product type, the Platelet Rich Plasma market is segmented by Pure-Platelet Rich Plasma (P-PRP), Leukocyte-Platelet Rich Fibrin (L-PRF) and Leukocyte-Platelet Rich Plasma (L-PRP).
On the basis of applications, the Platelet Rich Plasma market is segmented by Orthopedics, Sports Medicine, Dentistry, Otolaryngology, Neurosurgery, Ophthalmology, Urology, Wound Healing and Others.
Latest Industry Highlights:
In Jan 2019, Healeon Medical announced the new high-density platelet Rich plasma series. The company developed a PRP solution to meet the need for expanding demand for platelet-rich plasma..
Some of the other players that are also part of study are Stryker Corporation and Healeon Medical, Inc.. The Global Platelet Rich Plasma market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Platelet Rich Plasma market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Platelet Rich Plasma market.
Identification of total players or companies operating in the global market which is further concentrated to a fewer or most impacting players which is considered under the reports scope. In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Platelet-rich plasma Manufacturers, Suppliers, and Distributors, Government Regulatory and Research Organizations and End-Use Industries.
This helps us to gather the data for the players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.